[2026] 🩸 Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study. | doi |
with O. Hermine, O. Debeaupuis, G. Damaj, J. Luebke, J. Schwaab, M. Heizmann, F. Siebenhaar, P. Pyatilova, N. Nojarov, M. Niedoszytko, A. Gorska, M. Mattsson, K. Shoumariyeh, S. de Bra, F. Wortmann, N. von Bubnoff, H. Bumbea, D. Soare, C. Elena, J. Varkonyi, A.B. Fortina, S. Erdem, K. Brockow, T.M. Franz, J. Panse, D. Christen, C. Breynaert, A.S. Yavuz, L. Malcovati, M. Doubek, V. Sabato, I. Tanasi, M. Bonifacio, K. Hartmann, A. Ruefer, M. Sciume, V. Bellani, I. Angelova-Fischer, A. Stefan, M. Triggiani, R. Parente, S.K. Klein, M. Makris, S. Papageorgiou, P. van Daele, I. Dybedal, D. Baffoe, T. Guelen, M. Jentzsch, O. Lortholary, M. Heiblig, C.B. Livideanu, S. Barete, C. Gourguechon, S. Dimicoli-Salazar, O. Tournilhac, L. Frenzel, M. Arock, A. Mital, J.N. Woltsche, H.C. Kluin-Nelemans, J.N.G. Oude Elberink, J. Gotlib, M. Sperr, A. Reiter, P. Valent, W.R. Sperr, J. Rossignol. Journal of Hematology & Oncology, 2026.

[2026] 🩸 Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study. | doi |
with M. Weiss, J. Rossignol, F. Campeotto, E. Foy, C. Elbany, L. Jaume, L. Geroux, O. Debeaupuis, A. Neuraz, L. Bekel, G. Lezmi, N. Bellon, C. Méni, C. Livideanu, M. Madrange, D. Condé, J. Agopian, C. Michot, F. Villard-Truc, A. Lachaux, C. Greco, S. Hadj-Rabia, P. Dubreuil, O. Hermine, C. Bodemer, L. Polivka, et al. Pediatric Allergy and Immunology, 2026.

[2025] 🧮 CausalCCC: a web server to explore intracellular causal pathways enabling cell--cell communication. | doi |
with O. Debeaupuis^†, L. Dupuis^†, F. Simon, H. Isambert. Nucleic Acids Research, 2025.

[2025] 🩸 In silico modeling guides identification of novel JAK1 variants associated with immune dysregulation. | doi |
with O. Debeaupuis^†, M. Jeanpierre^†, et al. EMBO Molecular Medicine, 17(12):3275, 2025.

[2025] 🩸 Whole exome sequencing in children with autoimmune hepatitis identified mutations in genes involved in the mTORC1 signaling pathway. | doi |
with L.P. Gaigne, C. Besnard, O. Debeaupuis, et al. Gastro Hep Advances, 100808, 2025.

[2025] 🩸 Inflammatory disorders in IDH-mutated myeloid neoplasms: characteristics and response to IDH inhibitors. | doi |
with R. Stammler, O. Debeaupuis^*, P. Chen^*, et al. HemaSphere, 9(11):e70256, 2025.

[2019] 🩸 Biology of RNA surveillance in development and disease. | doi |
with B. Laffleur, U. Basu, et al. Trends in cell biology, 29 (5), 428-445, 2019.

[2017] 🩸 B cell intrinsic mechanisms constraining IgE memory. | doi |
with B. Laffleur, O. Debeaupuis, Z. Dalloul, M. Cogné. Frontiers in Immunology, 8:1277, 2017.

[2016] 🩸 Repair mechanisms of DNA interstrand cross-link in Escherichia coli MDS42 induced by the alkylating agent SJG-136.
with O. Debeaupuis, M. Gottesman. Columbia Medical Center Archives, 2016.

[2026] 🧮 CayleyPy-4: AI-Holography. Towards analogs of holographic string dualities for AI tasks. | doi |
with A. Chervov, F. Levkovich-Maslyuk, A. Smolensky, F. Khafizov, I. Kiselev, D. Melnikov, I. Koltsov, S. Kudashev, D. Shiltsov, M. Obozov, S. Krymskii, V. Kirova, E.V. Konstantinova, A. Soibelman, S. Galkin, L. Grunwald, A. Kotov, A. Alexandrov, S. Lytkin, D. Fedoriaka, ..., H. Isambert, O. Debeaupuis. arXiv preprint arXiv:2603.22195, 2026.

[2026] 🧮 ResearchArena-CayleyBench: RL/LLM Benchmark challenges which can advance mathematical research. | doi |
AAAI 2026, AI4Research, Singapore, Singapore.

[2025] 🧮 CayleyPy Growth: Efficient growth computations and hundreds of new conjectures on Cayley graphs. | doi |
with A. Chervov, D. Fedoriaka, E. Konstantinova, A. Naumov, ..., O. Debeaupuis, ..., et al. Workshop on Mathematical Reasoning and AI at NeurIPS, 2025.

[2025] 🧮 Hierarchical biomarker thresholding: a model-agnostic framework for stability. | doi |
O. Debeaupuis. arXiv preprint arXiv:2511.18030, 2025.

[2025] 🧮 CayleyPy Growth: Efficient growth computations and hundreds of new conjectures on Cayley graphs (Brief version). | doi |
with A. Chervov, et al. arXiv preprint arXiv:2509.19162, 2025.

[2025] 🧮 Causal inference for reliable biomarker discovery with applications to cancer and autoimmune interactions. | doi |
O. Debeaupuis. PhD thesis, Université Paris Cité, 2025.

[2022] 🩸 Omics analysis and biomarker discovery in a rare indolent disease, RALD, and in a high-grade neoplasm, juvenile myelomonocytic leukemia. | doi |
O. Debeaupuis. Exercice thesis, 2022.

[2026] Novel prognostic risk scoring system for patients with advanced systemic mastocytosis treated with midostaurin or avapritinib: development and validation of the revised mutation-adjusted risk score. | doi |
with J. Luebke, A. Zakharyan, J. Gotlib, J. Rossignol, D.J. DeAngelo, D.H. Radia, T.I. George, M. Deininger, O. Debeaupuis, N. Naumann, G. Metzgeroth, A. Fabarius, W.-K. Hofmann, S. Dimitrijevic, O. Hermine, J. Schwaab, A. Reiter. EHA 2026, Stockholm, Sweden.

[2026] Recurrent somatic mutations in KRAS drive a specific autoinflammatory phenotype associated with myeloid neoplasms
Presentation. EULAR 2026, London, United Kingdom.

[2026] 🩸 Efficacite et tolerance de l'avapritinib dans la mastocytose systemique indolente : premiers resultats de l'etude en vie reelle francaise AIMS. | doi |
with C. Gourguechon, C. Bulai Livideanu, M. Heiblig, E. Le Mouel, S. Barete, Y. Chantran, L. Lhermitte, O. Debeaupuis, H. Bouktit, O. Hermine, J. Rossignol. La Revue de Medecine Interne, 47(S1):A54, 2026.

[2026] 🩸 Les mutations somatiques de KRAS definissent un phenotype auto-inflammatoire specifique associe aux neoplasies myeloides. | doi |
with P. Chen, O. Debeaupuis, A. Le Pogam, L.P. Zhao, F. Castellan, L. Estibaliz, S. Dimicoli-Salazar, D. Clayton, C. Etienne, E. Clappier, H. Dupuy, A. Bidet, F. Chasset, M. Ruyer-Thompson, R. Stammler, R. Itzykson, O. Fain, T. Comont, P. Hirsch, P. Fenaux, A. Mekinian, J. Rossignol, V. Jachiet, S. Savic, D. Beck, E. Solary, F. Rieux-Laucat, D. Selimoglu-Buet, J. Hadjadj. La Revue de Medecine Interne, 47(S1):A77--A78, 2026.

[2026] ResearchArena-CayleyBench: RL/LLM Benchmark challenges which can advance mathematical research.
AAAI 2026, AI4Research, Singapore, Singapore.

[2025] Efficacy and tolerability of avapritinib in indolent systemic mastocytosis: first results from the French AIMS real-world study.
Presentation. EAACI 2025, Glasgow, Scotland.

[2025] CayleyPy Growth: Efficient growth computations and hundreds of new conjectures on Cayley graphs.
Poster. NeurIPS 2025, MATH-AI, San Diego, USA.

[2025] Inflammatory rheumatological manifestations associated with IDH-mutated myeloid neoplasms effectively treated with IDH inhibitors.
Oral presentation. EULAR 2025, Barcelone, Spain.

[2025] Roundtable participant.
ECNM 2025, London, United Kingdom.

[2025] Biomarqueur des neutrophiles circulants dans le diagnostique de l'artérite à cellules géantes (ACG).
Oral presentation. SNFMI 2025, Nancy, France.

[2025] T cell fate: causal network reconstruction and dynamic modeling for personalized patient care.
Oral presentation. IT2025 – Immunotherapies Congress, La Havana, Cuba.

[2024] Characterization of novel JAK1 gain-of-function variants: implications for personalized JAK inhibitor therapy.
Oral presentation. ESID 2024 – European Society for Immunodeficiencies, France.

[2024] Functional analysis of JAK1 GOF mutations.
Seminar. Pierre Royer Seminar Series, France.
[2025] Caractéristiques cliniques, immunologiques, pronostiques et thérapeutiques des hémopathies myéloïdes mutées IDH avec manifestations systémiques inflammatoires.
with R. Stammler, P. Chen, O. Debeaupuis, et al. La Revue de Médecine Interne, 46:A115--A116, 2025.

[2023] Identification des mutations somatiques et analyse des mécanismes immunologiques au cours des manifestations auto-immunes associées aux leucémies.
with A. Le Pogam, O. Debeaupuis, et al. La Revue de Médecine Interne, 44:A354, 2023.

[2023] Caractérisation immunologique des manifestations auto-immunes et inflammatoires associées aux syndromes myélodysplasiques.
with C. Etienne, O. Debeaupuis, et al. La Revue de Médecine Interne, 44:A355, 2023.

[2023] Roundtable participant.
WiML Workshop @ NeurIPS in Paris, Paris, France.

[2023] Ranking DEGs by calculation condition on a target class.
Poster. Bonn Mathematical Life Science Conference, Germany.

[2022] Predicting leukemic transition in RAS-mutated JMML.
Poster. YRLS Congress, France.

[2021] Investigating cytoplasmic RNA heteroduplexes in yeast.
Short talk. Institut Pasteur RNA Biology Series, France.

[2016] UrvD at play in post-ICL recombination in E. coli.
Poster. Columbia University Medical Center retreat, USA.